Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Time to Sell?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down before the market opened on Wednesday . The stock had previously closed at $11.95, but opened at $11.41. Telix Pharmaceuticals shares last traded at $11.3190, with a volume of 71,306 shares traded.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $22 price target, implying substantial upside from recent trading levels. The bullish view indicates confidence in Telix’s growth prospects and the strategic rationale for the ITM transaction. Tickerreport.com: Wedbush Reaffirms Outperform Rating
• Positive Sentiment: Telix agreed to acquire ITM in a transaction valued at up to $2.35 billion, including $1.65 billion payable upfront and as much as $700 million in contingent consideration tied to regulatory approval and sales targets. The deal could secure critical cancer-treatment isotope supply, expand Telix’s radiopharmaceutical reach and create a larger oncology platform. Inside Monkey: Telix to Buy ITM
• Positive Sentiment: RBC upgraded Telix from “hold” to “moderate buy,” providing additional support for the stock after the acquisition announcement. Tickerreport.com: RBC Upgrades Telix
• Neutral Sentiment: Telix’s research and development presentation and merger call highlighted its oncology pipeline and strategic plans, but investors will likely need further details on integration, funding and the transaction’s effect on future earnings. Seeking Alpha: Telix Research and Development Day
• Negative Sentiment: The market’s initial reaction was negative because the acquisition is large relative to Telix and is expected to involve significant share issuance. Investors are concerned about dilution, valuation, integration risk and the possibility that the transaction will pressure near-term returns, helping explain the recent share-price decline. RTT News: Telix Stock Drops Following ITM Deal

Analyst Ratings Changes

Several analysts have issued reports on TLX shares. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Finally, Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Telix Pharmaceuticals currently has an average rating of “Buy” and an average target price of $20.50.

Telix Pharmaceuticals Trading Down 5.9%

The business’s 50 day moving average is $11.32 and its two-hundred day moving average is $10.41. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TLX. Bank of America Corp DE lifted its holdings in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares in the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals during the first quarter valued at $120,000. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $1,731,000. Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.